
Shares of genetics testing firm Tempus AI TEM.O rise 3.3% to $60.63
Company slightly raised its 2025 revenue forecast to $1.26 billion, from its previous projection of $1.25 billion
Company posts quarterly revenue of $314.6 million compared with $165.97 million a year ago
Says it saw significant re-acceleration of clinical volumes which grew 30% in the reported quarter, as co delivered more than 212,000 next-generation sequencing tests
Up to last close, stock up 38.8% YTD